Eli Lilly Report Result of Donanemab in P-II TRAILBLAZER-ALZ Study for Alzheimer’s Disease

 Eli Lilly Report Result of Donanemab in P-II TRAILBLAZER-ALZ Study for Alzheimer’s Disease

Eli Lilly Report Result of Donanemab in P-II TRAILBLAZER-ALZ Study for Alzheimer’s Disease

Shots:

  • The P-II study involves assessing donanemab vs PBO in 272 patients with early symptomatic AD who were selected based on cognitive assessments in conjunction with amyloid plaque imaging and tau staging by PET imaging
  • The study met its 1EPs, showed a slowing of decline by 32% @76wks. as measured by the iADRS. The secondary analyses showed consistent improvements in cognition & function decline on all 2EPs but did not reach nominal statistical significance on every 2EPs
  • 40% of patients achieved amyloid negativity as early as 6mos. after starting treatment and 68% achieved the target by 18mos. Lilly plans to discuss the results with regulators to evaluate the next steps for donanemab

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: BioSpace

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post